International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

Use in newly diagnosed CLL patients

The CLL‑IPI stratifies CLL patients into four risk groups using age, stage, TP53 status, IGHV status, and β2‑microglobulin to predict survival.

Age
≤ 65 years0> 65 years+1
Clinical stage
Binet A or Rai 00Binet B-C or Rai I-IV+1
Serum beta2 microglobulin, mg/L (or microg/mL)
≤ 3.50> 3.5+2
IGHV mutational status
Mutated0Unmutated+2
TP53 status
No abnormalities0Deletion 17p (FISH) and/or TP53 mutation (sequencing)+4

Indikationen

Identifies prognosis at diagnosis or before first‑line therapy to stratify overall survival and time‑to‑first‑treatment in untreated CLL, including early‑stage disease. Guides watch‑and‑wait vs early‑intervention trial enrollment and highlights patients needing targeted agents when TP53‑aberrant. Robustly validated across >3,500 patients with strong OS/PFS discrimination 1 [Level I evidence] and confirmed in contemporary cohorts 2 [Level I evidence].

Hinweise & Vorsichtsmaßnahmen

Stratifies risk using age, stage, TP53 status, IGHV status, and β2‑microglobulin, predicting survival and time‑to‑first‑treatment. Validated across >3000 patients with c‑statistic ~0.72 for OS 1 [Level I evidence]. Retains prognostic value with targeted agents for PFS but less for OS 2 [Level II evidence]. Use cautiously: very‑high‑risk group overlap, diminished discrimination in novel‑therapy era, and does not guide treatment selection.